

# Pharmaceutical Industry

## Topics and Reading List for Spring 2013

CCP Pharmaceutical Reading Group

*School of Economics and Center for Competition Policy  
University of East Anglia, Norwich, Norfolk NR4 7TJ*

Spring 2013

---

(1) Jan/25 (Franco) – Cost and Utilization of Generics and Brands

- **Patricia M. Danzon and Michael F. Furukawa. Cross-national evidence on generic pharmaceuticals: Pharmacy vs. physician-driven markets. NBER Working Paper w17226, National Bureau of Economic Research, July 2011.**
- Ernst R. Berndt and Joseph P. Newhouse. Pricing and reimbursement in U.S. pharmaceutical markets. NBER Working Paper w16297, National Bureau of Economic Research, August 2010.
- Patricia M. Danzon and Michael F. Furukawa. International prices and availability of pharmaceuticals in 2005. *Health Affairs*, 27(1):221–233, January 2008. doi: 10.1377/hlthaff.27.1.221.
- Patricia M. Danzon and Li-Wei Chao. Cross-national price differences for pharmaceuticals: how large, and why? *Journal of Health Economics*, 19(2):159–195, March 2000. doi: 10.1016/S0167-6296(99)00039-9. URL [http://dx.doi.org/10.1016/S0167-6296\(99\)00039-9](http://dx.doi.org/10.1016/S0167-6296(99)00039-9).

(2) Feb/8 (Silvia) – Authorized Generics and Reverse Payments

- **Silvia Appelt. Authorized generic entry prior to patent expiry: reassessing incentives for independent generic entry. Munich Discussion Paper No. 2010-23, April 2010. URL <http://epub.ub.uni-muenchen.de/11476/>.**
- Aidan Hollis. The anti-competitive effects of brand-controlled “pseudo-generics” in the Canadian pharmaceutical market. *Canadian Public Policy - Analyse de Politiques*, 29(1):21–32, 2003.
- David Reiffen and Michael R. Ward. ‘branded generics’ as a strategy to limit cannibalization of pharmaceutical markets. *Managerial and Decision Economics*, 28(4-5): 251–265, 2007.
- C. Scott Hemphill. Paying for delay: Pharmaceutical patent settlement as a regulatory design problem. *New York University Law Review*, 81(30):101–167, November 2006.
- C. Scott Hemphill. Drug patent settlements between rivals: A survey, March 12 2007. URL [http://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=969492](http://papers.ssrn.com/sol3/papers.cfm?abstract_id=969492).

Note: Silvia will be on campus that day and hence we will meet at 3pm (after her presentation from 1-2pm at CCP) so as to discuss more technical details of her paper.

## (3) Feb/22 (Morten) – Prices in post-generic entry

- **Steven N. Wiggins and Robert Maness. Price competition in pharmaceuticals: The case of anti-infectives.** *Economic Inquiry*, 42(2):247–263, April 2004.
- Richard G. Frank and David S. Salkever. Pricing patent loss and the market for pharmaceuticals. *Southern Economic Journal*, 59(2):165–179, October 1992.
- David Reiffen and Michael R. Ward. Generic drug industry dynamics. FTC Bureau Economics Working Paper 248, Federal Trade Commission, October 2002. URL <http://ssrn.com/abstract=390102>.

## (4) March/8 (Anna) – Parallel Trade

- **Anna Rita Bennato and Tommaso Valletti. Pharmaceutical innovation and parallel trade.** CCP Working Paper 12-9, Center for Competition Policy, University of East Anglia, May 2012.
- Gene M. Grossman and Edwin C.L. Lai. Parallel imports and price controls. *RAND Journal of Economics*, 39(2):378–402, Summer 2008.
- Mattias Ganslandt and Keith E. Maskus. Parallel import and the pricing of pharmaceutical products: Evidence from the European Union. *Journal of Health Economics*, 23(5):1035–1057, September 2004. doi: 10.1016/j.jhealeco.2004.03.005.
- Stefan Szymanski and Tommaso Valletti. Parallel trade, price discrimination, investment and price caps. *Economic Policy*, 20(44):705–749, October 2005. doi: 10.1111/j.1468-0327.2005.00149.x.

## (5) March/22 (Georg) – Agreement on Trade Related Aspects of IP Rights (TRIPS)

- **Shubham Chaudhuri, Pinelopi K. Goldberg, and Panle Jia. Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India.** *American Economic Review*, 96(5):1477–1514, December 2006. URL <http://www.jstor.org/stable/30034983>.
- Ashish Arora, Lee Branstetter, and Chirantan Chatterjee. Strong medicine: Patent reform and the emergence of a research-driven pharmaceutical industry in India. mimeo. Also in NBER Book Volume on The Location of Biopharmaceutical Activity, 2012 (Forthcoming), Iain M. Cockburn & Matthew J. Slaughter, editors., 2008.

## (6) April/5 (Farasat) – Follow-on Drugs

- **Farasat A.S. Bokhari and Gary M. Fournier. Entry in the ADHD drugs market: Welfare impact of generics and me-toos.** *Journal of Industrial Economics*, forthcoming. URL [http://ideas.repec.org/p/fsu/wpaper/wp2009\\_05\\_01.html](http://ideas.repec.org/p/fsu/wpaper/wp2009_05_01.html).
  - Peter Arcidiacono, Paul Ellickson, Peter Landry, and David B. Ridley. Pharmaceutical followers. mimeo, September 2012. URL [public.econ.duke.edu/~psarcidi/generics.pdf](http://public.econ.duke.edu/~psarcidi/generics.pdf).
  - Joseph A. DiMasi and Cherie Paquette. The economics of follow-on drug research and development: Trends in entry rates and the timing of development. *PharmacoEconomics*, 22(2 (Suppliment 2)):1–14, 2004.
-

(7) April/19 (TBA) – Prescription-only to over-the-counter switch

- Ernst R. Berndt, Margaret K. Kyle, and Davina C. Ling. The long shadow of patent expiration: generic entry and rx-to-otc switches. In "Robert C. Feenstra and Matthew D. Shapiro", editors, *Scanner data and price indexes*, pages 229–273. University of Chicago Press. URL [URL:http://www.nber.org/chapters/c9737](http://www.nber.org/chapters/c9737).
- ???
- ???

(8) May/3 (TBA) – Other topics of interest??

(9) May/17 (TBA) – Other topics of interest??

(10) May/31 (TBA) – Other topics of interest??

---